NDAORALTABLET
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
WEGOVY (semaglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEGOVY (semaglutide) is an oral GLP-1 receptor agonist approved for obesity and expanding into multiple cardiometabolic and metabolic indications including type 2 diabetes, chronic kidney disease, heart failure with preserved ejection fraction, and NASH. It works by mimicking glucagon-like peptide-1, suppressing appetite, reducing food intake, and improving glycemic control and cardiovascular outcomes.
$0.2MPart D
Growth12.7 years to LOEWEGOVY is in early commercial launch with significant expansion potential across obesity and multiple cardiometabolic indications, signaling growing brand team staffing and marketing investment.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Started Jul 2026
164 enrolled
Muscle WastingObesity & OverweightObesity
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Started Jun 2026
3,000 enrolled
Obesity & Overweight
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Started Jun 2026
150 enrolled
Pediatric ObesityMetabolic and Bariatric SurgerySemaglutide
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Started May 2026
1,000 enrolled
ObesityOverweightDiabetes Mellitus, Type 2
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Started Apr 2026
100 enrolled
Obesity
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.